Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$117.8m

Seres Therapeutics Past Earnings Performance

Past criteria checks 0/6

Seres Therapeutics's earnings have been declining at an average annual rate of -19.8%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 26% per year.

Key information

-19.8%

Earnings growth rate

5.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate26.0%
Return on equityn/a
Net Margin-90.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27
Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Sep 03
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Jul 03
Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Jun 08

Seres Therapeutics gets FDA clearance for SER-155 IND trials

Jun 01

Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

May 20
Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 05

Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Apr 05
Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Revenue & Expenses Breakdown
Beta

How Seres Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:MCRB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23126-114880
30 Sep 23127-141930
30 Jun 23130-153910
31 Mar 235-265840
31 Dec 227-250800
30 Sep 2213-231780
30 Jun 22137-103790
31 Mar 22141-87760
31 Dec 21145-66690
30 Sep 21155-34590
30 Jun 2130-132470
31 Mar 2131-105360
31 Dec 2033-89310
30 Sep 2023-90260
30 Jun 2029-76240
31 Mar 2035-66230
31 Dec 1935-70250
30 Sep 1938-73260
30 Jun 1940-78280
31 Mar 1932-95310
31 Dec 1828-99330
30 Sep 1821-107340
30 Jun 1835-92340
31 Mar 1833-92340
31 Dec 1732-89340
30 Sep 1732-86340
30 Jun 1722-97340
31 Mar 1722-97340
31 Dec 1622-92330
30 Sep 1619-86300
30 Jun 166-82270
31 Mar 163-67210
31 Dec 150-55170
30 Sep 150-44135
30 Jun 150-3498
31 Mar 150-24610
31 Dec 140-1840
30 Sep 140-1237

Quality Earnings: MCRB is currently unprofitable.

Growing Profit Margin: MCRB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MCRB is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerating Growth: Unable to compare MCRB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MCRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: MCRB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.